Understanding how anti-CTLA-4 and anti-PD-1 checkpoint blockade therapies work will be critical for effectively combining them with other anti-cancer therapeutic approaches such as immune-, radio-, chemo- and targeted therapy to improve overall response rate [2]. Here, PDCD1 is linked to cancer.